Cargando…
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial
BACKGROUND: Vaccination of children and young people against SARS-CoV-2 is recommended in some countries. Scarce data have been published on immune responses induced by COVID-19 vaccines in people younger than 18 years compared with the same data that are available in adults. METHODS: COV006 is a ph...
Autores principales: | Li, Grace, Cappuccini, Federica, Marchevsky, Natalie G, Aley, Parvinder K, Aley, Robert, Anslow, Rachel, Bibi, Sagida, Cathie, Katrina, Clutterbuck, Elizabeth, Faust, Saul N, Feng, Shuo, Heath, Paul T, Kerridge, Simon, Lelliott, Alice, Mujadidi, Yama, Ng, Khuen Foong, Rhead, Sarah, Roberts, Hannah, Robinson, Hannah, Roderick, Marion R, Singh, Nisha, Smith, David, Snape, Matthew D, Song, Rinn, Tang, Karly, Yao, Andy, Liu, Xinxue, Lambe, Teresa, Pollard, Andrew J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9183219/ https://www.ncbi.nlm.nih.gov/pubmed/35691324 http://dx.doi.org/10.1016/S0140-6736(22)00770-X |
Ejemplares similares
-
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials
por: Voysey, Merryn, et al.
Publicado: (2023) -
An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females
por: Marchevsky, Natalie Gabrielle, et al.
Publicado: (2022) -
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
por: Clemens, Sue Ann Costa, et al.
Publicado: (2021) -
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
por: Flaxman, Amy, et al.
Publicado: (2021) -
Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A Randomised Controlled Trial
por: Kelly, Eimear, et al.
Publicado: (2023)